Phase 2 study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3ss) inhibitor, as a single agent or combined with Ruxolitinib, in patients with myelofibrosis
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Actuate Therapeutics
Start Date
May 14, 2020
End Date
February 13, 2024
Administered By
Duke Cancer Institute
Awarded By
Actuate Therapeutics
Start Date
May 14, 2020
End Date
February 13, 2024